GenSight Biologics Announces the Filing of its 2025 Universal Registration Document

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that its 2025 Universal Registration Document (URD) in English was filed with the French market authority (Autorités des Marchés Financiers, or AMF) on April 14, 2026, under the reference D.26-0251. The Univ.